SC
SNDX icon

SummitTX Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

SummitTX Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Buy
66,340
+27,213
+70% +$591K 0.05% 352
2025
Q4 		$822K Sell
39,127
-61,459
-61% -$1.07M 0.02% 444
2025
Q3 		$1.55M Sell
100,586
-110,658
-52% -$1.45M 0.06% 306
2025
Q2 		$1.98M Buy
211,244
+47,011
+29% +$517K 0.09% 251
2025
Q1 		$2.02M Buy
+164,233
New +$2.32M 0.09% 247

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

SummitTX Capital's SNDX Position: Q1 2026 in Review

SummitTX Capital increased its Syndax Pharmaceuticals (SNDX) stake by 70% in Q1 2026, buying an estimated $591K and bringing the position to 66,340 shares worth $1.55M. The position accounts for 0.05% of the portfolio, ranked #352.

SummitTX Capital first reported a position in SNDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.02M in Q1 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • SummitTX Capital held 66,340 shares of Syndax Pharmaceuticals worth $1.55M as of Q1 2026.
  • SummitTX Capital bought 27,213 Syndax Pharmaceuticals shares in Q1 2026, an estimated $591K.
  • Syndax Pharmaceuticals made up 0.05% of SummitTX Capital's portfolio in Q1 2026, its #352 holding.
  • SummitTX Capital first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Syndax Pharmaceuticals position peaked at $2.02M in Q1 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.